MPP VARR

• Research type

  Research Study

• Full title

  The effect of MultiPoint™ pacing on reverse remodelling and the incidence of ventricular arrhythmias – The MPP VARR Study

• IRAS ID

  180454

• Contact name

  C. Aldo Rinaldi

• Contact email

  aldo.rinaldi@gstt.nhs.uk

• Sponsor organisation

  Guy's & St Thomas' Foundation NHS Trust

• Duration of Study in the UK

  2 years, 0 months, 0 days

• Research summary

  Heart failure patients may benefit from having a special pacemaker implanted that can make the heart pump in a more co­ordinated and efficient way called Cardiac Resynchronisation Therapy (CRT). For the heart to pump well it is necessary for the pacing lead to be placed in optimal positions within the main chambers of the heart. Current pacing leads stimulate the main chamber of the heart from one location. Only two thirds of people respond to CRT and this may be due to the need to stimulate the heart from more than one position. Previous attempts at using two pacing leads in the main chamber of the heart have proved technically difficult. Due to new technologies it is now possible to stimulate the heart from more than one site using one lead - MultiPoint™ Pacing (MPP). This lead can also function as a conventional pacing lead if the MPP mode is switched off. The aim of this study is to use this specialised lead in the main chamber of the heart and study the outcomes of patients with the MPP on and MPP off. We hypothesise that MPP will increase the proportion of responders to CRT and that this will also result in a reduction in the frequency of abnormal heart rhythms. Pilot study work has shown that the work is technically feasible and safe. This study will be a multi­centre randomised controlled trial whereby all patients will receive CRT therapy with MPP leads and be randomised to either MPP on or MPP off. If the patients in the MPP on arm fare better than those receiving standard CRT therapy then this may alter how a large proportion of heart failure patients are treated around the world. The study requires 282 patients and is likely to take two years to complete.

• REC name

  East Midlands - Nottingham 1 Research Ethics Committee

• REC reference

  16/EM/0344

• Date of REC Opinion

  1 Sep 2016

• REC opinion

  Further Information Favourable Opinion